The present application describes compounds that inhibit the kinase Family Iraq (interleukin 1), Methods for production thereof, Pharmaceutical compositions comprising the sameAnd Methods of treatment using the same, for the prophylaxis and / or treatment of inflammatory diseasesAutoimmune diseases and / or proliferative diseases by Administering the compound of the present.Claim 1: a compound according to formula (1), where Cy is optionally substituted cycloalkyl c u2083 u208b u2087 monocyclic with one or more Selected r u00b3 Regardless,Heterocicloalquilo monocyclic or 4 - 7 members comprising one or two heteroatoms selected irrespective of N, S, and oOptionally substituted with one or more r u00b3 selected independently； r u00b9 is H, so u2083h, P (= o) (OH) u2082, alkyl c u2081 u208b u2084,C u208d u208co u208e u208b u208d u2095 u2091 u209c u2091 u02b3 u2092 u1d9c u2071 u1d9c u2097 u2092 u2090 u2097q u1d58 u2071 u2097 u2092 u2098 u2092 u2099 u2092 u1d9c u00ed u1d9c u2097 u2071 u1d9c u2092 u1d48 u2091 by Land. u208b u2087 u2098 u2071 u2091 u2098 u1d47 u02b3 u2092 u209b q u1d58 u2091 u1d9c u2092 u2098 u209a u02b3 u2091 u2099 u1d48 u2091 u1d58 u2099 u2092 u2092 u1d48 u2092 u209b u2095 u2091 u209c u2091 u02b3 u2092 u00e1 u209c u2092 u2098 u2092 u209b u209b u2091 u2097 u2091 u1d9c u1d9c u2071 u2092 u2099 u2090 u1d48 u2092 u209b u2071 u2099 u1d48 u2091 u209a u2091 u2099 u1d48 u2071 u2091 u2099 u209c u2091 u2098 u2091 u2099 u209c u2091 u1d48 u2091 n, S u02b8 o u208e, u2092 c u208d u208co u208e u2090 u2097q u1d58 u2071 u2097 u2092 c u2081 u208b u2086,Rent c u2081 u208b u2086 is optionally substituted with one or More groups r u2074 selected independently； R u00b2 is H or alkyl c u2081 u208b u2084； each r u00b3 is selected regardless of: o = o, haloAlkyl and c u2081 u208b u2084； each is selected regardless of r u2074: nr u2075 u1d43r u2075 u1d47, C (= o) Oh,Heterocicloalquilo monocyclic 4 - 7 members comprising one or two heteroatoms selected irrespecti
